Meliodays Medical GmbH, a young pharmaceutical company focusing on the development of a new therapy for the hormone-free and locally acting treatment of menstrual pain, today announces the successful closing of an oversubscribed pre-seed financing round of over 800,000 euros led by capacura GmbH and with participation of FS Life Science Investment GmbH and other early-stage investors and business angels specialized in the healthcare market..

Meliodays Medical GmbH是一家年轻的制药公司，专注于开发一种新的无激素且局部作用的月经疼痛治疗方法，今天宣布成功完成了由capacura GmbH领投、FS Life Science Investment GmbH和其他医疗市场早期投资者及商业天使参与的超过80万欧元的超额认购前种子轮融资。

Symbol image

符号图像

Computer-generated image

计算机生成的图像

Simone Sabbione, co-founder and CEO of Meliodays Medical, said: 'We are delighted that we were able to attract such experienced healthcare and impact investors for our first financing round and warmly welcome them to the Meliodays shareholder base. Their investment and the great interest in our significantly oversubscribed pre-seed round show that period pain is now recognized as a serious health burden for large parts of the global population.

梅洛迪医疗公司的联合创始人兼首席执行官西蒙·萨比奥内表示：“我们很高兴在首轮融资中吸引了如此经验丰富医疗保健和影响力投资者，并热烈欢迎他们加入梅洛迪的股东行列。他们的投资以及对我们大幅超额认购的前种子轮融资的极大兴趣表明，经痛现已被认为是全球很大一部分人口面临的严重健康负担。”

Now we can finally work on much-needed solutions.'.

现在我们终于可以致力于急需的解决方案了。

Around 80 percent of menstruating people suffer from period pain, 20-30 percent of which is so severe that it temporarily limits their ability to attend school, work and social activities and often requires the use of pain medication. However, the treatment options currently available, such as hormone therapies or high-dose painkillers, are often associated with systemic side effects..

大约 80% 的经期人群会遭受痛经之苦，其中 20-30% 的人症状严重到暂时无法上学、工作或参加社交活动，通常还需要服用止痛药。然而，目前可用的治疗方案，如激素疗法或高剂量止痛药，常伴随着全身性的副作用。

With the fresh capital, Meliodays Medical will advance the development of MelioOne, a novel, hormone-free, locally acting treatment for menstrual pain, and finalize preparations for preclinical testing of its innovative intra-uterine application. By using a proven polymer technology, a very small amount of painkiller is released specifically in the uterus, effectively combating period pain and avoiding systemic side effects.

通过这笔新资金，Meliodays Medical 将推动无激素、局部作用的经痛治疗药物 MelioOne 的开发，并完成其创新宫内应用的临床前测试准备。通过使用经过验证的聚合物技术，极少量止痛药会特异性释放于子宫内，有效缓解经期疼痛，同时避免全身性副作用。

In the future, Meliodays Medical's innovative technology could also be used in the treatment of endometriosis. The company has already secured the patent rights for MelioOne in over 150 countries..

未来，Meliodays Medical的创新技术还可用于治疗子宫内膜异位症。该公司已经获得了MelioOne在150多个国家的专利权。

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar.

请注意：本文已使用计算机系统进行翻译，未经过人工干预。LUMITOS 提供这些自动翻译的文章以呈现更广泛的时事新闻。由于本文是通过自动翻译生成的，因此可能会在词汇、句法或语法方面存在错误。

The original article in German can be found .

德语原文可以在以下位置找到。

here

这里

.

。

https://www.bionity.com/en/news/1185871/meliodays-medical-announces-completion-of-a-pre-seed-financing-of-800-000-euros.html

https://www.bionity.com/zh/news/1185871/meliodays-medical-宣布完成80万欧元的预种子轮融资.html

Pain relief without side effects and addiction

无副作用和成瘾性的止痛

Better than opiates: Researchers use adrenaline receptors for highly-effective analgesics

比阿片类药物更好：研究人员利用肾上腺素受体开发高效止痛药

Read news

读新闻

Most read news

最热门的新闻

1

1

Natural substance spray against pulmonary fibrosis

天然物质喷雾对抗肺纤维化

2

2

Rare side effect discovered in cancer immunotherapy

癌症免疫治疗中发现的罕见副作用

3

3

Fascinating new findings: Obesity starts in the brain

令人着迷的新发现：肥胖始于大脑

4

4

Antimalarial drug together with anticancer drug is efficient against leukemia

抗疟疾药物与抗癌药物一起对白血病有效。

5

5

A method to purify proteins with light

一种用光纯化蛋白质的方法

Topics

主题

pain medications

止痛药

Show all

显示全部

Show less

显示更少

Organizations

组织机构

Meliodays Medical

梅洛迪医疗